Skip to main content
. 2016 May 4;73(20):3839–3859. doi: 10.1007/s00018-016-2253-7

Table 2.

Roles of CIRP and RBM3 in cancer

Cancer type CIRP or RBM3 studied Proposed mechanisms Prognosis associated with high expression References
Breast cancer Both RBM3 – Good [181]
CIRP Increase cyclin E1 Poor [82, 142]
Epithelial ovarian cancer RBM3 Inhibit MCM3, Chk1 and Chk2 Good [171, 182]
Endometrial carcinoma CIRP – Unclear [141]
Prostate cancer RBM3 Involve ERG and PTEN; enhance chemo-sensitivity; regulate CD44 splicing Good and unclear [135, 163, 183–185]
Testicular non-seminomatous germ cell cancer RBM3 – Good [187]
Urothelial bladder cancer RBM3 – Good or not determined [188, 189]
Oropharyngeal squamous cell carcinoma Both RBM3 – Not determined [193]
CIRP Induce TLR4-related inflammation Poor [140]
Esophageal and gastric adenocarcinoma RBM3 – Good [194]
Liver cancer CIRP Increase ROS, IL-1β and IL-6; suppress p53 Poor [99, 137]
Colorectal cancer Both RBM3 Suppress GSK3β activity and enhance β-catenin signaling Good [169, 190–192]
CIRP Induce TNF-α and IL-23 Poor [138]
Melanoma RBM3 Inhibit MCM3 Good [195–197]
Astrocytoma RBM3 – Unclear [198]
Pituitary adenoma CIRP Induce cyclin D1 and decrease p27 via Erk1/2 signaling Poor [102, 139]
OSZAR »